Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSCT APL2021 ATRA and arsenic trioxide remission induction and consolidation for acute promyelocytic leukemia
jRCTs071210035Active, not recruiting
- Start
- Jul 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of tretinoin, arsenic trioxide and idarubicin in Acute promyelocytic leukaemia (APL) (2 arms). Primary endpoint: Disease-free survival. Started Jul 2021; status: active, not recruiting.
02
Drugs
tretinoinarsenic trioxideidarubicin
03
Conditions
Acute promyelocytic leukaemia (APL)
Beyond the preview
Go deeper on jRCTs071210035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071210035.